Need Help?

RNA-sequencing data from metastatic Castration-Resistant Prostate Cancer (mCRPC)

The goal of this study is to characterize the transcriptional landscape of advanced prostate cancer

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001008487 Illumina HiSeq 4000 224
EGAD00001009065 Illumina HiSeq 1500 Illumina HiSeq 4000 164
Publications Citations
Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.
Cell 174: 2018 758-769.e9
Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity.
Mol Cancer Res 17: 2019 1235-1240
Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
Eur Urol 76: 2019 562-571
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.
JAMA Oncol 7: 2021 1644-1652
Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.
Nat Commun 13: 2022 5345
Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer.
Clin Cancer Res 28: 2022 5396-5404
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer.
Clin Cancer Res 29: 2023 2324-2335
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.
Cancer Res 83: 2023 2763-2774